A. Dreas

发表

How to design potent and selective DYRK1B inhibitors? Molecular modeling study

M. Milik, M. Król, M. Vilenchik, 2019, Journal of Molecular Modeling.

(4S)-(−)-4-Benzyl-2,2-dimethyl-3-o-toluoyl-1,3-oxazolidine

M. Chrzanowska, A. Dreas, Zofia Meissner, 2010, Acta crystallographica. Section E, Structure reports online.

(S)‐(–)‐2,3‐Dimethoxy‐8‐oxoberbine

M. Chrzanowska, A. Froelich, A. Dreas, 2006 .

(3R,4R)-(–)-3-Hydroxymethyl-4-phenyl-2-o-toluoyl-1,2,3,4-tetrahydroisoquinoline

Michał S. Kaczmarek, M. Chrzanowska, A. Dreas, 2006 .

(S)-(–)-2,3-Methylenedioxy-8-oxoberbine

M. Chrzanowska, A. Dreas, A. Gzella, 2005 .

SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains

M. Mikuła, J. Ostrowski, A. Wróbel, 2017, Oncotarget.

Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors.

M. Milik, M. Mikulski, K. Brzózka, 2017, Current medicinal chemistry.

The asymmetric synthesis of (R)-(+)- and (S)-(−)-O-methylbharatamine

M. Chrzanowska, A. Dreas, 2004 .

Asymmetric synthesis of (R)-(+)- and (S)-(−)-2,3-methylenedioxy-8-oxoberbine (gusanlung D)

M. Chrzanowska, A. Dreas, M. Rozwadowska, 2004 .

Synthesis of (S)-(−)- and (R)-(+)-O-methylbharatamine using a diastereoselective Pomeranz–Fritsch–Bobbitt methodology

M. Chrzanowska, A. Dreas, M. Rozwadowska, 2005 .

Discovery of indazole-pyridinone derivatives as a novel class of potent and selective MNK1/2 kinase inhibitors that protecting against endotoxin-induced septic shock.

M. Milik, M. Mikuła, J. Ostrowski, 2020, European journal of medicinal chemistry.

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma

Sidong Huang, W. Miller, Jie Su, 2017, The Journal of clinical investigation.